Colorado BioScience Association
Colorado BioScience Association

2013 Proves Successful Year for Bioscience in Colorado

Colorado BioScience Association (CBSA) highlights Colorado’s key financings and acquisitions in the industry during 2013. The Association plays a key role in promoting Colorado as a dynamic region for bioscience innovation and investment.

Denver, CO, December 18, 2013 --(PR.com)-- Colorado realized a number of key financings and acquisitions in the bioscience industry during 2013. The announcement is made by April Giles, President & CEO of the Colorado BioScience Association (CBSA), who says "We saw several exciting deals this year with many more on the horizon as Colorado continues to gain national recognition in the bioscience industry."

CBSA plays a key role in promoting Colorado as a dynamic region for bioscience innovation and investment, by working with government and community stakeholders to develop ways to support the creation, retention and recruitment of life sciences companies.

Highlighted Financing and Acquisitions in 2013 Include (deals over $8M):

• Biodesix Closes $8.8M Series D Financing - April 11, 2013
Boulder based Biodesix, Inc., announced that the company closed on $8.8 million in a follow-on sale of its Series D preferred shares. http://www.biodesix.com/biodesix-closes-series-d-financing-2/

• Takeda to Acquire Inviragen for $250M – May 8, 2013
Fort Collins based Inviragen agreed to be acquired by Takeda, the largest pharmaceutical company in Japan for $35 million cash and $215 million in milestones. http://www.takeda.com/news/2013/20130508_5757.html

• Lanx Completes $15M Series C Equity Financing – May 13, 2012
Broomfield based Lanx, Inc., announced the closing of a $15 million Series C equity financing. http://www.lanx.com/pdfs/PR9900-0113_Series%20C%20Equity%20Financing%20Release.pdf

• Clovis Oncology Raises an Additional $275M – June 18, 2013
Boulder based Clovis Oncology’s initial IPO in 2011 was $139 million on the sale of 10.7 million shares. They raised an additional $75 million in 2012 and $275 million in June of 2013 through public offerings. http://www.xconomy.com/boulder-denver/2013/06/18/clovis-oncology-closes-275m-offering-following-two-pivotal-weeks/

• SomaLogic Inc. Raised $10M in Equity Financing – August 20, 2013
Boulder based SomaLogic Inc. raised $10 million in equity financing from unidentified investors. http://www.bizjournals.com/denver/blog/boosters_bits/2013/08/somalogic-raises-venture-capital.html

• Baxter Completes Acquisition of Gambro AB for $4B – September 6, 2013
Lakewood based Gambro BCT, a wholly owned entity of Gambro AB was acquired by Baxter International Inc. of Deerfield, Ill. for $4 billion. http://www.baxter.com/press_room/press_releases/2013/09_06_13_gambro.html

• Ampio Pharmaceuticals, Inc. Announces $25M Financing – September 26, 2013
Greenwood Village based Ampio Pharmaceuticals, Inc., announced a financing transaction that will provide $25 million in gross proceeds to the company. http://ampiopharma.com/news/ampio-pharmaceuticals-inc-announces-25-million-financing/

• Surefire Medical Closes Series B Funding at $18.2M - November 7, 2013
Westminster based Surefire Medical, Inc. completed a $18.2 million Series B funding. The latest financing will be used to expand product development, clinical trials, operations and marketing to meet rapidly growing national and international customer demand. http://surefiremedical.com/news/surefire-medical-closes-series-b-funding-at-18-2-million/

“Large financings and acquisitions are key to raising Colorado’s profile to garner attention from investors and corporate leadership. Colorado has all of the pieces in place to be in the top 5 national bioscience clusters in the country— the science, the infrastructure, and the people," Giles explains.

About Colorado BioScience Association

Celebrating ten years of supporting the Bioscience Industry in Colorado in 2013, the CBSA is a not-for-profit organization providing services and support for Colorado's bioscience industry. With more than 350 members, CBSA actively works to promote the growth of the industry by advocating for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state, and speaking with a single voice on behalf of the industry. For more information, visit http://www.cobioscience.com.

CBSA also is found on these social media sites:

Twitter: http://www.twitter.com/COBioscience
LinkedIn Group: http://www.linkedin.com/groups?about=&gid=98468&trk=anet_ug_grppro
Facebook Fan Page: http://www.facebook.com/ColoradoBioScienceAssociation
News Feed: http://coloradobio.blogspot.com
YouTube Channel: http://www.youtube.com/COBioscience
Pinterest: http://pinterest.com/COBioscience
Tumblr: http://cobioscience.tumblr.com

Contacts:

Mae Desaire, Director of Marketing, Colorado BioScience Association - http://www.cobioscience.com –
720-382-5918, mdesaire@cobioscience.com

Maggie Chamberlin Holben, APR, Absolutely Public Relations - http://www.absolutelypr.com - 303-984-9801, maggie@absolutelypr.com
Contact
Colorado BioScience Association
Maggie Holben
303-984-9801
http://www.cobioscience.com
ContactContact
Categories